Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 2661 | 7.4 |
09:34 ET | 300 | 7.33 |
09:36 ET | 504 | 7.3704 |
09:39 ET | 100 | 7.27 |
09:43 ET | 193 | 7.27 |
09:48 ET | 300 | 7.36 |
09:50 ET | 300 | 7.32 |
09:56 ET | 300 | 7.41 |
09:57 ET | 125 | 7.3549 |
09:59 ET | 200 | 7.3699 |
10:01 ET | 200 | 7.36 |
10:03 ET | 100 | 7.365 |
10:10 ET | 200 | 7.32 |
10:12 ET | 300 | 7.36 |
10:15 ET | 408 | 7.33 |
10:21 ET | 1886 | 7.28 |
10:28 ET | 100 | 7.33 |
10:30 ET | 730 | 7.29 |
10:32 ET | 600 | 7.27 |
10:33 ET | 100 | 7.27 |
10:35 ET | 345 | 7.276 |
10:39 ET | 1768 | 7.22 |
10:42 ET | 1154 | 7.22 |
10:46 ET | 300 | 7.2 |
10:48 ET | 105 | 7.135 |
10:50 ET | 1693 | 7.1228 |
10:51 ET | 1200 | 7.15 |
10:53 ET | 4200 | 7.16 |
10:55 ET | 100 | 7.19 |
10:57 ET | 100 | 7.16 |
11:02 ET | 200 | 7.15 |
11:06 ET | 2300 | 7.13 |
11:08 ET | 600 | 7.12 |
11:09 ET | 699 | 7.14 |
11:13 ET | 100 | 7.12 |
11:15 ET | 300 | 7.13 |
11:18 ET | 713 | 7.12 |
11:20 ET | 1812 | 7.105 |
11:22 ET | 714 | 7.14 |
11:24 ET | 100 | 7.12 |
11:26 ET | 816 | 7.08 |
11:27 ET | 700 | 7.115 |
11:29 ET | 400 | 7.09 |
11:31 ET | 1300 | 7.1 |
11:33 ET | 4221 | 7 |
11:36 ET | 3332 | 7.01 |
11:38 ET | 1597 | 6.98 |
11:44 ET | 3220 | 7.09 |
11:45 ET | 922 | 7.12 |
11:51 ET | 2644 | 7.1399 |
11:56 ET | 1720 | 7.19 |
11:58 ET | 140 | 7.2108 |
12:02 ET | 2066 | 7.15 |
12:03 ET | 100 | 7.15 |
12:07 ET | 280 | 7.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 155.8M | -0.9x | --- |
Century Therapeutics Inc | 144.0M | -0.8x | --- |
Achieve Life Sciences Inc | 158.0M | -4.1x | --- |
Acumen Pharmaceuticals Inc | 150.2M | -2.2x | --- |
Ventyx Biosciences Inc | 162.5M | -0.9x | --- |
Inovio Pharmaceuticals Inc | 168.2M | -1.2x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $155.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.